ArticleDiabetes care2020
Reports of Lactic Acidosis Attributed to Metformin, 2015-2018.
Article in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Animal studies on the modulation of differential efficacy of polyethylene glycol loxenatide by intestinal flora.Frontiers in endocrinology · 2025Article
- Trends in Antidiabetic Drug Use and Safety of Metformin in Diabetic Patients with Varying Degrees of Chronic Kidney Disease from 2010 to 2021 in Korea: Retrospective Cohort Study Using the Common Data Model.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights.Vascular health and risk management · 2024Review
- The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.Physiological research · 2021Review
- Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.International journal of molecular sciences · 2021Review
- Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study.Endocrinology, diabetes & metabolism · 2021Article
- Metformin: A Novel Weapon Against Inflammation.Frontiers in pharmacology · 2021Review
- Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury inFrontiers in pharmacology · 2021Article
- Ameliorating Metabolic Profiles After Kidney Transplantation: A Protocol for an Open-Label, Prospective, Randomized, 3-Arm, Controlled Trial.Frontiers in medicine · 2021Article
- Metformin Protects against Podocyte Injury in Diabetic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2020;43:244-246.Diabetes care · 2020Article
- Review
- Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.Frontiers in pharmacology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
objectiveIn 2016, the U.S. Food and Drug Administration (FDA) revised metformin's label to permit use in patients with mild-moderate chronic kidney disease. We sought to determine whether this change was associated with increased reports of metformin-associated lactic acidosis (MALA) to the FDA's Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND
methodsPublicly available FAERS reports were analyzed.
resultsMALA reports increased from 521 in 2015 to 1,939 in 2018. After restriction to U.S. reports, absolute and relative increase in MALA reports was less, from 111 to 243. The proportionate reporting ratio (PRR), a measure adjusted for rates of other adverse event reports, was stable.
conclusionsThe increased reports deserve attention, but the PRR's stability and FAERS's known limitations, including lack of a denominator or control group, do not permit the conclusion that U.S. MALA rates have increased. Further study with more robust data sources is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.